United States · FDA National Drug Code directory
BAT
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 60492-0075_c49e701b-f65d-4493-85f8-21a2e8d8974d
- Product NDC
- 60492-0075
- Form
- LIQUID
- Composition / generic term
- Botulism Antitoxin Heptavalent
- Labeler
- Emergent BioSolutions Canada Inc
- Marketing category
- BLA
- Marketing start / end (source format)
- 20130301
- Source listing expiry
- 20271231
Source-listed ingredients
- EQUINE BOTULINUM NEUROTOXIN A IMMUNE FAB2 — 4500 [iU]/10mL
- EQUINE BOTULINUM NEUROTOXIN B IMMUNE FAB2 — 3300 [iU]/10mL
- EQUINE BOTULINUM NEUROTOXIN C IMMUNE FAB2 — 3000 [iU]/10mL
- EQUINE BOTULINUM NEUROTOXIN D IMMUNE FAB2 — 600 [iU]/10mL
- EQUINE BOTULINUM NEUROTOXIN E IMMUNE FAB2 — 5100 [iU]/10mL
- EQUINE BOTULINUM NEUROTOXIN F IMMUNE FAB2 — 3000 [iU]/10mL
- EQUINE BOTULINUM NEUROTOXIN G IMMUNE FAB2 — 600 [iU]/10mL
These values do not establish equivalence or a dose recommendation.
Packages
- 6 VIAL, GLASS in 1 CARTON (60492-0075-2) / 50 mL in 1 VIAL, GLASS (60492-0075-1) · 60492-0075-2
- 1 VIAL, GLASS in 1 CARTON (60492-0075-4) / 50 mL in 1 VIAL, GLASS (60492-0075-1) · 60492-0075-4
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →